ASSAY and Drug Development Technologies
ASSAY and Drug Development Technologies provides access to novel techniques and robust tools that enable critical advances in early-stage screening. This research published in the Journal leads to important therapeutics and platforms for drug discovery and development. This reputable peer-reviewed journal features original papers application-oriented technology reviews, topical issues on novel and burgeoning areas of research, and reports in methodology and technology application.
ASSAY and Drug Development Technologies coverage includes:
- Assay design, target development, and high-throughput technologies
- Hit to Lead optimization and medicinal chemistry through preclinical candidate selection
- Lab automation, sample management, bioinformatics, data mining, virtual screening, and data analysis
- Approaches to assays configured for gene families, inherited, and infectious diseases
- Assays and strategies for adapting model organisms to drug discovery
- The use of stem cells as models of disease
- Translation of phenotypic outputs to target identification
- Exploration and mechanistic studies of the technical basis for assay and screening artifacts
The Journal also features a dedicated Drug Repurposing, Rescue, and Repositioning (DRRR) section. These special peer-reviewed collections of papers present techniques and tools for finding new uses for approved drugs – particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.
This DRRR special section features original papers, application-oriented technology reviews, and reports in methodology and technology application to drug repurposing and redevelopment including:
Designing assays and interpreting output to enable alternate drug target identification
Pathway analysis and bioinformatics to identify and exploit drug promiscuity
In silico technologies to identify alternate drug targets
"Big Data" mining and side effect pattern analysis in clinical and healthcare repositories
ASSAY and Drug Development Technologies is under the editorial leadership of Editor-in-Chief Wai Hong (Kevin) Lo, PhD, Vanderbilt University School of Medicine; and other leading investigators.
Journal Audience Includes: Drug discovery and assay development scientists, drug delivery and formulation specialists, molecular and behavioral pharmacologists, pharmaceutical and biotechnology researchers, and disease foundation advocates, among others.
| Wai Hong Lo, PhD | University of Connecticut Health Center, Farmington, CT, USA |
| Michelle Arkin, PhD | Univ Of California San Francisco, San Francisco, CA, USA |
| Haian Fu, PhD | Emory University School of Medicine, Atlanta, GA, USA |
| Thomas Lundbäck, PhD | AstraZeneca, Gothenburg, Sweden |
| Doug Auld, PhD | Novartis Institutes for BioMedical Research, Cambridge, MA, USA |
| Anton Simeonov, PhD | National Institutes of Health, Bethesda, MD, USA |
| Guleid Awale, PhD | Pfizer, Groton, CT, USA |
| Mohammed A. Barajaa, PhD | Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia |
| Stephen J Benkovic | Pennsylvania State University, University Park, PA, USA |
| Laura Berliocchi, PhD | Magna Graecia University, Catanzaro, Italy |
| Maumita Bhattacharjee, PhD | Celularity Inc, Florham Park, NJ, USA |
| Leo S. Bleicher, AB | |
| Bruce E. Bloom, JD, DDS | Healx Ltd., Deerfield, IL, USA |
| Diane J. Burgess, PhD | University of Connecticut, Storrs, CT, USA |
| Susan Catalano, PhD | Cognition Therapeutics Inc, Pittsburgh, PA, USA |
| Francesco S Celi, MD, MHSC | University of Connecticut Health Center, Farmington, CT, USA |
| Hugh Hiu Nam Chan, PhD | Cleveland Clinic, Cleveland, OH, USA |
| Harsh Chauhan, PhD | Creighton University, Omaha, NE, USA |
| Daniel Chelsky, PhD | |
| Namjin Chung, PhD | |
| Hakim Djaballah, PhD | |
| Stephen C. Ekker, PhD | University of Texas at Austin, Austin, TX |
| Darryl Falzarano, PhD | University of Saskatchewan, Saskatoon, SK, Canada |
| Frank Fan, PhD | |
| Thomas L. Fare, PhD | |
| Dan Fitzpatrick, PhD | |
| Georgios V. Gkoutos, BSc, MSc, PhD, DIC | |
| J. Fraser Glickman, MPH, PhD | Rockefeller University, New York, NY, USA |
| Samuel Hasson, PhD | |
| Christopher Heise, PhD | Genentech Inc, South San Francisco, CA, USA |
| Ilkka Hemmilä, PhD | |
| Paul A Johnston, PhD | University Of Pittsburgh School Medicine, Pittsburgh, PA, USA |
| Robert J. Lefkowitz, MD | |
| Jay Liu, PhD | Rugen Therapeutics, Shanghai, China |
| Ralph R Martel | High Throughput Genomics Inc, Tucson, AZ, USA |
| Lorenz Mayr, PhD | |
| Patricia McDonald, PhD | The Scripps Research Institute, Jupiter, FL, USA |
| Xiulei Mo, PhD | Emory University, Atlanta, GA, USA |
| Walter D Niles, PhD | Aurora Biotechnologies Inc, La Jolla, CA, USA |
| Kevin R. Oldenburg, PhD | Matrical, Spokane, WA, USA |
| Hiroyuki Osada, PhD | |
| Takayoshi Otsuka, PhD | Niigata University, Niigata, Japan |
| Young-Whan Park, PhD | National Oncoventure At National Cancer Center, Gyeonggi-Do, South Korea |
| Jeffrey H Price, MD, PhD | Burnham Institute For Medical Research, La Jolla, CA, USA |
| John R. Raymond, MD | Medical College of Wisconsin, Milwaukee, WI, USA |
| E. Mitchell Seymour, PhD, RAC | |
| Kaylene J. Simpson, PhD | |
| Gary Skinner, PhD | |
| Sharon F. Terry, MA | |
| Jeffrey H. Toney, PhD | Kean University, Union, NJ, USA |
| Bret Ulery, PhD | University of Missouri, Columbia, MO, USA |
| Richard B. van Breemen, PhD | |
| Henry VanBrocklin, PhD | University of California, San Francisco, USA |
| Christian R Voolstra, PhD | University of Konstanz, Konstanz, Germany |
| Joseph Walker, MD | University of Connecticut, Farmington, CT, USA |
| Jun Wang, PhD | Lynk Pharmaceuticals, Zhejiang, China |
| Charles D. Weaver, PhD | Vanderbilt Medical School, Nashville, TN, USA |
| Holly Yin, PhD | City Of Hope National Medical Center, Duarte, CA, USA |
| Guido JR Zaman, PhD | |
| Zhong Zhong, PhD | Generation Bio, Cambridge, MA, USA |
| Jim Inglese, PhD | Bethesda, MD, USA |
| Bruce J. Melancon, PhD | Nashville, TN, USA |